File | Description | Date |
---|---|---|
SSDC Contract Year 2024 Solicitation Letter 169.5 KB | 2023/03/23 | |
Medicaid Supplemental Rebate Agreement 155.82 KB | 2023/02/28 | |
Labeler Guide 67.76 KB | 2022/04/08 | |
Labeler Guide 307.55 KB | 2022/03/01 | |
SPA, PDL and Supplemental Rebate Approval Letter - 2018 612.07 KB | 2018/07/05 | |
Frequently Asked Questions Regarding Drug Rebate Program 247.18 KB | 2016/05/02 |
Please visit the www.rxssdc.org website to complete and submit the Supplemental Rebate Offer spreadsheet. The multi-state pool is open for negotiations for agreements that become effective January 1st annually. As a result, the Consortium has established deadlines for the submission of initial completed Supplemental Rebate Offers. Offers received after that date will not be considered until the next annual open offer period. The only potential exceptions will be for new products subsequently entering the market. The Member States of the SSDC will not present any bids for Preferred Drug List (PDL) consideration without signed agreements.
Any questions regarding how to submit bids may be directed to the SSDC Negotiations Team at GHS via email at rxoffers@rxssdc.org.
Make checks payable to: Iowa Medicaid: Drug Rebate
Companies wishing to discuss opportunities for Supplemental Rebates should visit the website for Manufacturers and Supplemental Rebates or call the Supplemental Rebate Coordinator at (877) 399-8556.
File | Description | Date |
---|---|---|
PDL New Drug Process 9.36 KB | 2007/04/18 |
File | Description | Date |
---|---|---|
Policy for Review of Drug Status 15.06 KB | 2007/11/09 |
If you have questions or comments about the Iowa Medicaid Preferred Drug List (PDL) that are not presently addressed on this website, for the quickest response, send an e-mail to info@iowamedicaidpdl.com. All submissions to this email address become public documents. Comments are posted on the website with hardcopies of the comments presented to the P&T Committee members at each meeting.
There are currently no files available.